Clinical Trial: A Phase 2 open-label clinical study using intravenous Paxceed™ to treat patients with rheumatoid arthritis

This study is no longer recruiting patients.

Sponsored by: Angiotech Pharmaceuticals
Information provided by: Angiotech Pharmaceuticals


Paxceed™ is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of Rheumatoid Arthritis (RA). The main objective of this study is to determine the effectiveness of treatment with Paxceed™ in patients with RA. In RA, there is an increase in cell growth and changes in cell function. The active substance in Paxceed™, paclitaxel, has undergone clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an agent that stops growth of cells and blocks certain types of cell function associated with RA. Because of these effects, it is thought that Paxceed™ might alter the destructive course of RA.

Condition Treatment or Intervention Phase
Rheumatoid Arthritis
 Drug: Micellar Paclitaxel for Injection
Phase II

MedlinePlus related topics:  Rheumatoid Arthritis

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Further Study Details: 

Expected Total Enrollment:  50

Study start: September 2002;  Study completion: December 2004


Ages Eligible for Study:  21 Years   -   70 Years,  Genders Eligible for Study:  Both


Inclusion Criteria:

(i) Signed informed consent in accordance with applicable regulations

(ii) Males and females aged 21 to 70 years inclusive

(iii) Must have failed at least one DMARD

(iv) Rheumatoid Arthritis fulfilling 1987 ACR revised criteria

(v) Active RA as defined by:

  • ≥6 swollen and ≥9 tender joints
  • CRP ≥0.8 mg/dL or morning stiffness ≥45 minutes

(vi) If female and of child bearing potential, she must:

  • have a negative serum pregnancy test, and
  • be using two forms of an effective method of contraception (one form being a barrier method) or be surgically incapable of bearing children or abstinent.

If male and heterosexual, he must:

  • agree to use condoms with spermicide throughout the study and for at least 12 weeks following the last infusion.
  • vasectomy is an acceptable form of contraception for males and partners of females

(vii) Adequate venous access as defined by the Principal Investigator

(viii) If taking non-steroidal anti-inflammatory medications, must be on stable regimen for four weeks prior to the Screening visit

(ix) If taking prednisone (≤ 10 mg) or equivalent, must be on stable regimen for four weeks prior to Screening visit

Exclusion Criteria:

(i) Prior or current treatment with alkylating agents, or radiation

(ii) Treatment with colchicine within six months prior to Screening

(iii) Experimental anti-rheumatic drugs within 90 days (or five half-lives, whichever is longer) prior to screening

(iv) DMARD therapy four weeks prior to Baseline visit

(v) Intra-articular corticosteroids four weeks prior to the Screening visit

(vi) Bedridden or wheelchair bound patients

(vii) Pregnant or lactating females

(viii) Interstitial lung disease

(ix) Clinically significant cardiac risk factors, including a history of congestive heart failure, angina, and myocardial infarction within the previous six months

(x) History of malignancy, except (a) basal cell carcinoma of the skin and in situ cervical carcinoma that have been excised with no recurrence or treatment within the last five years, and (b) low-grade prostate cancer

(xi) Major organ allograft, or uncontrolled cardiac, hepatic, pulmonary, renal or central nervous system disease, know clotting deficiency, or any illness that increases undue risk to patient

(xii) History of anaphylactic reactions

(xiii) WBC count <4,000/mm3; Neutrophils <2,000/mm3; Platelet count <125,000/mm3; hemoglobin <9g/dL; creatinine >1.4 times the upper limit of normal; liver function test >1.2 times the upper limit of normal

(xiv) Presence of Hepatitis B Surface antigen (HbsAg), Hepatitis C antibody (HCVAb), and/or Hepatitis C quantitative assay, or history of hepatitis (such as autoimmune hepatitis) within one year prior to Screening

(xv) Presence of any confounding illness or syndromes that may interfere with proper evaluation of efficacy, such as other autoimmune disease, psoriatic arthritis, lupus or scleroderma

(xvi) Patients determined by the investigator (e.g., because of known or probable alcohol or drug abuse) to be unreliable for follow-up

Location Information

      University of Alabama at Birmingham, Birmingham,  Alabama,  35294-7201,  United States

      Denver Arthritis Clinic, Denver,  Colorado,  80230,  United States

      Tampa Medical Group Research, Tampa,  Florida,  33614,  United States

      Radiant Research, Daytona Beach,  Florida,  32114,  United States

      Ocala Rheumatology Research Center, Ocala,  Florida,  34474,  United States

      Indiana University, Indianapolis,  Indiana,  46202,  United States

      Arthritis & Rheumatology Clinic of Kansas, Wichita,  Kansas,  67214-4976,  United States

      Arthritis Center of Reno, Reno,  Nevada,  89502,  United States

      Altoona Center for Research, Duncansville,  Pennsylvania,  16635-1018,  United States

More Information

Study ID Numbers:  008-MPRA02
Record last reviewed:  November 2003
Last Updated:  October 13, 2004
Record first received:  February 19, 2003 Identifier:  NCT00055133
Health Authority: United States: Food and Drug Administration processed this record on 2005-04-08

Cache Date: April 9, 2005